In PTEN-deficient prostate cancer, prostate-specific deletion of CHD1 resulted in markedly delayed tumor progression and prolonged survival, which was associated with a reduction in MDSCs and an increase in CD8+ T cells through IL-6, a key transcriptional target of CHD1. The gene discussed is CHD1; the disease is prostate cancer.